SPHERA FUNDS MANAGEMENT LTD
Q3 2026 Form 13-F

TEL AVIV
CIK 0001496201 · CRD 312614 · Exempt reporting adviser
Consolidated report · includes 2 managers since Q4 2013
$707.5M Reported Value Total

SPHERA FUNDS MANAGEMENT LTD. reports under management (AUM).

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-17
Reported value
$707.5M
Quarter over quarter
-10.3%
Holdings
100
Top-10 concentration
33.1%

Filing Structure

Reports holdings for

  • Sphera Healthcare US Inc. (not a 13F filer in our records) · File #028-21415 · Q3 2021 – Q2 2022

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Oshrat Levi
Chief Financial Officer

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $707.5M
Positions 100
Change in reported value -7.7%
New positions 22
Exited positions 19
Position turnover 34.5%
Top-10 concentration 33.1%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
100 $707.5M
Q2 2026 13F
Filed Aug 14, 2026
97 $766.5M
Q1 2026 13F
Filed May 15, 2026
92 $629.7M
Q4 2025 13F
Filed Feb 17, 2026
94 $517.3M
Q3 2025 13F
Filed Nov 14, 2025
101 $474.1M
Q2 2025 13F
Filed Aug 14, 2025
101 $426.1M
Q1 2025 13F
Filed May 15, 2025
112 $434.3M
Q4 2024 13F
Filed Feb 14, 2025
103 $553.1M
Q3 2024 13F
Filed Nov 14, 2024
108 $628.4M
Q2 2024 13F
Filed Aug 14, 2024
110 $733.2M
Q1 2024 13F
Filed May 15, 2024
93 $711.7M
Q4 2023 13F
Filed Feb 14, 2024
89 $621.3M
Q3 2023 13F
Filed Nov 14, 2023
75 $549.0M
Q2 2023 13F
Filed Aug 14, 2023
76 $640.4M
Q1 2023 13F
Filed May 15, 2023
75 $598.4M
Q4 2022 13F
Filed Feb 14, 2023
58 $465.9M
Q3 2022 13F
Filed Nov 14, 2022
65 $720.5M
Q2 2022 13F
Filed Aug 15, 2022
50 $934.9M
Q1 2022 13F
Filed May 16, 2022
59 $707.6M
Q4 2021 13F
Filed Feb 14, 2022
85 $909.6M

32 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 MLYS MINERALYS THERAPEUTICS INC $33.2M 4.7%
2 TEVA TEVA PHARMACEUTICAL INDS LTD $32.5M 4.6%
3 ALNY ALNYLAM PHARMACEUTICALS INC $29.8M 4.21%
4 CYTK CYTOKINETICS INC $23.9M 3.37%
5 SOXX ISHARES TR $21.0M 2.97%
6 BBIO BRIDGEBIO PHARMA INC $20.5M 2.9%
7 TSEM TOWER SEMICONDUCTOR LTD $19.3M 2.72%
8 SNDX SYNDAX PHARMACEUTICALS INC $18.9M 2.68%
9 BMRN BIOMARIN PHARMACEUTICAL INC $17.6M 2.49%
10 BIIB BIOGEN INC $17.1M 2.42%
11 COGT COGENT BIOSCIENCES INC $16.1M 2.27%
12 NVMI NOVA LTD $15.0M 2.13%
13 MDGL MADRIGAL PHARMACEUTICALS INC $13.0M 1.84%
14 XBI P SPDR SERIES TRUST $11.8M 1.67%
15 META META PLATFORMS INC $11.7M 1.66%
16 IMTX IMMATICS N.V $11.5M 1.62%
17 SNY SANOFI SA $11.1M 1.57%
18 AZN ASTRAZENECA PLC $11.1M 1.56%
19 ARKG P ARK ETF TR $10.8M 1.53%
20 MAZE MAZE THERAPEUTICS INC $10.0M 1.41%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings